论文部分内容阅读
目的 探讨血清中CA19 9水平与胰腺癌不同发展阶段之间的关系。方法 应用12 5Ⅰ标记的单克隆抗体基于三明治原理对 118例胰腺癌患者血清中CA19 9水平进行放射免疫测定。结果 CA19 9水平随着胰腺癌临床进展浸润而逐渐升高 ,在统计学上各临床分期之间的均数有显著性差异 (P <0 .0 1) ;胰腺癌患者血清CA19 9水平与肿瘤大小无关 (P >0 .0 5 ) ;胰腺癌伴或不伴发黄疸患者之间血清CA19 9水平无明显差别 (P >0 .0 5 )。结论 CA19 9是诊断胰腺癌较为重要的肿瘤标志物 ,它在指导临床分期 ,判断手术切除率及估计预后方面有一定的价值。
Objective To investigate the relationship between serum CA19 9 levels and different stages of pancreatic cancer. Methods Serum CA19 9 levels of 118 patients with pancreatic cancer were determined by radioimmunoassay with sandwich method based on sandwich principle. Results The level of CA19 9 gradually increased with the clinical progression of pancreatic cancer. There was a statistically significant difference between all clinical stages (P <0.01). The serum level of CA19 9 in patients with pancreatic cancer was significantly lower than that in tumors There was no significant difference in the serum CA19 9 levels between patients with and without pancreatic cancer (P> 0.05). Conclusion CA19 9 is a more important tumor marker in the diagnosis of pancreatic cancer. It has certain value in guiding the clinical stage, judging the surgical resection rate and estimating the prognosis.